IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC